Point72 Asia Singapore Pte. Ltd. Buys 6,434 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

Point72 Asia Singapore Pte. Ltd. raised its stake in Protalix BioTherapeutics, Inc. (NYSE:PLX) by 13.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,507 shares of the company’s stock after acquiring an additional 6,434 shares during the period. Point72 Asia Singapore Pte. Ltd. owned about 0.07% of Protalix BioTherapeutics worth $101,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. PFG Investments LLC bought a new stake in shares of Protalix BioTherapeutics during the fourth quarter worth $39,000. Y Intercept Hong Kong Ltd acquired a new position in Protalix BioTherapeutics in the fourth quarter valued at about $35,000. Prudential Financial Inc. acquired a new position in Protalix BioTherapeutics in the fourth quarter valued at about $68,000. Renaissance Technologies LLC grew its stake in Protalix BioTherapeutics by 17.0% in the fourth quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company’s stock valued at $2,102,000 after acquiring an additional 162,100 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Protalix BioTherapeutics during the fourth quarter worth about $192,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Stock Performance

Shares of NYSE PLX opened at $1.67 on Friday. The firm has a market cap of $132.94 million, a P/E ratio of -12.85 and a beta of -0.05. Protalix BioTherapeutics, Inc. has a 1-year low of $0.82 and a 1-year high of $3.10. The business’s 50 day moving average is $2.47 and its 200-day moving average is $2.17.

Protalix BioTherapeutics (NYSE:PLX) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.05) EPS for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. Analysts forecast that Protalix BioTherapeutics, Inc. will post 0.01 EPS for the current year.

Wall Street Analysts Forecast Growth

PLX has been the subject of several recent research reports. HC Wainwright increased their price target on Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 12th.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.